N/A
N=1,349
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
Renal Cell Carcinoma
Bottom Line
View on ClinicalTrials.gov: NCT02776644 ↗Enrolled (actual)
1,349
Serious AEs
—
Results posted
Apr 2019
Primary outcome: Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Sunitinib and Pazopanib Treatment in Participants |
171; 114.5 | — |
| PRIMARY Cumulative Number of Capsules of Sunitinib and Pazopanib Administered From the Time of Start of Treatment Up to Month 3 |
190.1; 215.1 | — |
| PRIMARY Cumulative Number of Capsules of Sunitinib and Pazopanib Administered From Month 3 to Month 6 |
165.0; 193.2 | — |
| PRIMARY Cumulative Number of Capsules of Sunitinib and Pazopanib Administered From Month 6 to Month 9 |
174.9; 186.5 | — |
| PRIMARY Cumulative Number of Capsules of Sunitinib and Pazopanib Administered From Month 9 to Month 12 |
176.5; 212.1 | — |
| PRIMARY Cumulative Number of Capsules of Sunitinib and Pazopanib Administered From the Time of Start of Treatment Up to Month 12 |
435.4; 438.0 | — |
| PRIMARY Overall Renal Cell Carcinoma (RCC) Related Direct Medical Cost From the Diagnosis Date to the First Dose of Sunitinib and Pazopanib |
176,969,380; 45,442,288 | — |
| PRIMARY Overall Renal Cell Carcinoma (RCC) Related Direct Medical Cost From the First Dose of the Sunitinib and Pazopanib to the End of Observation Period |
1,519,649,383; 78,745,896 | — |
| PRIMARY Overall Survival |
490; 416 | — |
| PRIMARY Number of Participants With Changes in Prescription Patterns of Antihypertensive Medication From the Time of First Dose of Drug at Month 1 |
96; 9; 85; 14; 63; 14 | — |
| PRIMARY Number of Participants With Changes in Prescription Patterns of Antihypertensive Medication From the Time of First Dose of Drug at Month 3 |
142; 20; 176; 21; 57; 13 | — |
| PRIMARY Number of Participants With Changes in Prescription Patterns of Antihypertensive Medication From the Time of First Dose of Drug at Month 6 |
132; 18; 213; 24; 54; 11 | — |
| PRIMARY Number of Participants With Changes in Prescription Patterns of Antihypertensive Medication From the Time of First Dose of Drug at Month 12 |
104; 17; 262; 28; 47; 10 | — |
| PRIMARY Number of Participants Who Received Antihypertensive Medication at Baseline |
518; 77 | — |
| PRIMARY Number of Participants Who Received Antihypertensive Medication From Baseline to Month 1 |
66; 5 | — |
| PRIMARY Number of Participants Who Received Antihypertensive Medication From Month 1 to Month 3 |
30; 7 | — |
| PRIMARY Number of Participants Who Received Antihypertensive Medication From Month 3 to Month 6 |
15; 5 | — |
| PRIMARY Number of Participants Who Received Antihypertensive Medication From Month 6 to Month 12 |
18; NA | — |
Summary
The clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied. This study will retrospectively analyse the clinical outcome of advanced renal cell carcinoma captured in Taiwan National Health Insurance Research Database.
Eligibility Criteria
Inclusion Criteria
- advanced/metastatic renal cell carcinoma
Exclusion Criteria
- N/A
Data sourced from ClinicalTrials.gov (NCT02776644). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.